Search clinical trials for: Atezolizumab

Total 793 results

Genentech, Inc.

Completed

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Cancer

United States
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (PERUSE)

Breast Neoplasms

Italy, Netherlands, Belgium, United Kingdom, Argentina, Austria, Brazil, China, Ecuador, Estonia, Finland, France, Germany, Greece, Mexico, Peru, Poland, Portugal, Slovenia, Spain, United Arab Emirates, Canada, Hungary, Israel, Sweden, Tu... and more
Hoffmann-La Roche

Completed

A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

Solid Cancers

United States, Belgium, France, Spain
Ardigen
National Center for Research and Development, Poland

Unknown

BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

Melanoma | Non Small Cell Lung Cancer | Metagenome | Immunotherapy | Microbiome

Poland
Ardigen
Małopolskie Centre of Entrepreneurship

Unknown

AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.

Non Small Cell Lung Cancer | Immunotherapy | Neoantigens | Neoepitopes | Next Generation Sequencing (NGS) | Personalized Neoantigen Cancer Vaccine

Poland
Medical University of Graz

Terminated

Vorinostat (SAHA) in Uterine Sarcoma

Leiomyosarcoma | Endometrial Stromal Tumors | Carcinosarcomas Uterine

Austria
Memorial Sloan Kettering Cancer Center
University of Pennsylvania; Genentech, Inc.

Completed

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Breast Cancer

United States
Genentech, Inc.

Completed

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Malignant Melanoma

United States
University of Michigan Rogel Cancer Center

Withdrawn

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
Immune Design
Genentech, Inc.

Terminated

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

Sarcoma | Myxoid/Round Cell Liposarcoma | Liposarcoma | Synovial Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma

United States
MultiVir, Inc.

Unknown

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Lymphoma | Solid Tumor

United States
Sungkyunkwan University
Ministry of Food and Drug Safety, Korea

Unknown

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung | Immune-Related Adverse Events
BioLineRx, Ltd.
Genentech, Inc.

Terminated

A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study

Acute Myeloid Leukemia

Israel, Spain, United States, Czechia, Poland, Slovakia
Simon Tremblay, PharmD, PhD
Veloxis Pharmaceuticals

Unknown

Veloxis de Novo Kidney Transplant ECSWD

Kidney Transplantation | Immunosuppression

United States
Hoffmann-La Roche

Completed

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Cancers

United States, Netherlands
Academisch Medisch Centrum - Universiteit van Amsterdam...
UMC Utrecht

Completed

PDL-1 Targeting in Resectable Oesophageal Cancer (PERFECT)

Esophageal Cancer, Stage II | Esophageal Cancer Stage III

Netherlands
Genentech, Inc.

Completed

A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (B-F1RST)

Non-Small Cell Lung Cancer

United States
Hoffmann-La Roche

Completed

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, France, United Kingdom, Hong Kong
Nilogen Oncosystems
Henry Ford Health System

Unknown

Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NO3DEXPL)

Non Small Cell Lung Cancer

United States
National Institute of Diabetes and Digestive and...

Completed

Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816

Chronic Hepatitis C

United States
Yonsei University

Unknown

A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients

Non Small Cell Lung Cancer
Hoffmann-La Roche

Completed

A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Yale University

Terminated

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Asymptomatic Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH); ViaCell

Completed

Cord Blood Expansion on Mesenchymal Stem Cells

Leukemia | Myelodysplastic Syndrome

United States
Queen Mary University of London
Hoffmann-La Roche

Unknown

Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder (ABACUS)

Bladder Cancer

United Kingdom, France, Spain, Netherlands
Hoffmann-La Roche

Terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Solid Tumor

United States, Spain, Canada, United Kingdom, Denmark, France, Germany, Israel, Italy, Netherlands, Switzerland
Queen Mary University of London
Hoffmann-La Roche; Polaris Group

Withdrawn

Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin (iTRAP)

Carcinoma, Non-Small-Cell Lung
Università Politecnica delle Marche

Unknown

Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors (ICI-DISCOVER)

Melanoma | Renal Cell Carcinoma | Cancer | Lung Cancer

Italy
Hoffmann-La Roche

Completed

A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

Solid Tumors

United States, Denmark, Spain, Canada, France, Italy, Netherlands
Darell Bigner
Genentech, Inc.; Istari Oncology, Inc.

Withdrawn

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Malignant Glioma
Halozyme Therapeutics

Terminated

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder Adenocarcinoma

United States, Korea, Republic of, Thailand
European Organisation for Research and Treatment...
Hoffmann-La Roche; Leap Therapeutics, Inc.

Withdrawn

Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer (DYNAMIC)

Esophageal Cancer | Hepatobiliary Neoplasm | Biliary Tract Cancer | GastroEsophageal Cancer
Hoffmann-La Roche

Completed

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

HER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast Cancer

United States
Hoffmann-La Roche

Completed

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Lymphoma

United States, France, Germany, Italy, United Kingdom
Hoffmann-La Roche

Completed

A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors

Solid Tumors

United States, Denmark, Spain, Switzerland, Netherlands, Canada
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (BIRCH)

Non-Small Cell Lung Cancer

United States, Belgium, Hong Kong, Italy, Slovenia, Australia, Canada, Bulgaria, Germany, France, Georgia, Singapore, Spain, Bosnia and Herzegovina, Switzerland, Turkey, Japan, United Kingdom, Netherlands
Hoffmann-La Roche

Completed

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma (IMmotion150)

Renal Cell Carcinoma

United States, Spain, Czechia, United Kingdom, Romania, France, Italy, Germany, Poland
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK)

Non-Squamous Non-Small Cell Lung Cancer

United States, Italy, Canada, Austria, Finland, France, Greece, Korea, Republic of, Panama, Portugal, Spain, Turkey, United Kingdom, Taiwan, Brazil, Germany, Poland, Chile, Guatemala, Russian Federation, Switzerland, Thailand, Ukraine, Serb... and more
Hoffmann-La Roche

Completed

Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States, Korea, Republic of, Australia, Canada, Germany, Singapore
Hoffmann-La Roche

Completed

A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

Solid Tumors

United States, Netherlands, Denmark, Spain, Canada, France
Hoffmann-La Roche

Completed

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

Colorectal Cancer

Canada, United States, Italy, Korea, Republic of, United Kingdom, Belgium, Russian Federation, Hong Kong, Spain, Australia, Poland
Ardigen
National Center for Research and Development, Poland; The Institute of Bioorganic...

Unknown

Polish Microbiome Map

Melanoma | Healthy Volunteers | Metagenome | Immunotherapy | Microbiome

Poland
Janssen Research & Development, LLC
Genentech, Inc.

Completed

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX)

Carcinoma, Non-Small-Cell Lung

France, United States, Spain, Hungary, Poland
MTI University

Unknown

The Renal Safety in Patients With Chronic HCV Undergoing Sofosbuvir Containing Antiviral Therapy

Egyptian Patients, HCV Treatment, Kidney Function

Egypt
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Terminated

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Genentech, Inc.

Completed

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Tumor

United States, Korea, Republic of, Spain, France
Hoffmann-La Roche

Completed

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

Non-Small Cell Lung Cancer

United States, Spain, Korea, Republic of, Belgium, Turkey, United Kingdom, Germany, Poland, Canada, France, Thailand, Italy, Sweden
Hoffmann-La Roche

Completed

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Castrate-Resistant Prostate Cancer

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Hoffmann-La Roche

Completed

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

Colorectal Cancer

Spain, United States

3

Subscribe